Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is ...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Founder, President, CEO & Chairman
Total Annual Compensation: $885.8K
Senior VP & CFO
Total Annual Compensation: $454.1K
COO & Director
Total Annual Compensation: $574.0K
Senior Vice President of Special Projects
Total Annual Compensation: $487.9K
Senior Vice President of Development Sciences
Total Annual Compensation: $409.2K
Compensation as of Fiscal Year 2016.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress
Sep 10 17
Five Prime Therapeutics, Inc. announced that updated data from the ongoing Phase 1b trial of FP-1039/GSK3052230 (hereafter FP-1039) in mesothelioma patients were reported in an oral presentation at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. The presentation titled Multicenter, Nonrandomized, Open-Label Phase 1b Study of FP-1039/GSK3052230 with Chemotherapy. The mesothelioma arm of the open-label Phase 1b trial evaluated weekly infusions of FP-1039, an FGF ligand trap, in combination with first-line pemetrexed and cisplatin chemotherapy in patients with untreated, unresectable MPM. Following the dose escalation portion of the trial, 15 mg/kg weekly was identified as the maximum tolerated dose (MTD) for FP-1039 and established as the dose for expansion in patients with MPM. The primary study endpoints are safety and overall response rate (ORR), disease control rate (DCR) at 6 months, progression free survival (PFS) and exploratory translational objectives. The poster includes data from MPM patients who had received FP-1039 as of the March 17, 2017 cut-off. Safety Data: The most common adverse events across all dose levels (AEs; all grades) observed were: nausea (56%), decreased appetite (36%), fatigue (33%) and infusion reaction (36%); The vast majority of events were Grades 1-2; Three dose-limiting toxicities (DLTs) were observed at the 20 mg/kg dose (Grade 5 bowel perforation/ischemia; Grade 3 elevated creatinine level and Grade 3 infusion reaction); No DLTs were observed at the 15 mg/kg dose level and so MTD was established at 15 mg/kg. Toxicities associated with small-molecule FGFR inhibitors, such as hyperphosphatemia, retinal detachment and nailbed changes, have not been observed. Efficacy Data: In the 27 patients evaluable as of March 17, 2017, who had received FP-1039 at or below the 15 mg/kg MTD dose level: Preliminary ORR was 48%, with six-month DCR of 81%, evaluated per mRECIST 1.1; 13 confirmed Partial Responses (PRs) and 9 durable Stable Disease (SD) (lasting at least six months); Evaluable patients are defined as patients who enrolled at least 42 days (2 cycles) prior to the cutoff date; Median PFS at or below the 15 mg/kg MTD dose level was 7.4 months. Historical median time to progression for cisplatin/pemetrexed is 5.7 months. FGF2 IHC Exploratory Biomarker Data: FGF2 overexpression is associated with worse prognosis in MPM; Statistically significant correlation between PFS and cytoplasmic FGF2 H-score was observed for the 15 mg/kg expansion group. FP-1039: FP-1039 is a protein drug designed to intervene in FGF signaling. As a ligand trap, FP-1039 binds to FGF ligands circulating in the extracellular space (such as FGF2), preventing these signaling proteins from reaching FGFR1 on the surface of tumor cells. Treatment with FP-1039 treatment has not been shown to cause hyperphosphatemia, a side effect seen with small molecule inhibitors of FGF receptors, which block the activity of both cancer-associated FGFs and FGF-23. GlaxoSmithKline (GSK) was the sponsor of the trial.
Five Prime Therapeutics, Inc. Presents at Citi's 12th Annual Biotech Conference, Sep-06-2017 03:00 PM
Sep 4 17
Five Prime Therapeutics, Inc. Presents at Citi's 12th Annual Biotech Conference, Sep-06-2017 03:00 PM. Venue: The Mandarin Oriental Hotel, Boston, Massachusetts, United States. Speakers: Aron Marc Knickerbocker, COO & Director.
Five Prime Therapeutics, Inc. Appoints Bryan Irving as Senior Vice President, Research, with Effect from September 1, 2017
Aug 17 17
Five Prime Therapeutics, Inc. announced that Bryan Irving, Ph.D., will join Five Prime as Senior Vice President, Research, on Sept. 1, 2017. Prior to joining Five Prime, Dr. Irving was at CytomX Therapeutics, where he most recently served as Vice President of Cancer Immunology, leading efforts to generate protease-activatable immunotherapies designed to mobilize anti-tumor immunity locally in the tumor microenvironment. His research has focused primarily on exploring ways to modulate T cell activity for therapeutic benefit in both autoimmune and oncology settings. Dr. Irving’s doctoral work, performed in the laboratory of Dr. Art Weiss at University of California, San Francisco, pioneered the single-chain chimeric antigen receptor (CAR) technology now being used in patient’s T cells to treat hematologic malignancies.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|